CASE REPORT: THE POSSIBILITY OF SPECIFIC THERAPY OPTIMIZATION BY SWITCHING FROM BOSENTAN TO MACITENTAN IN A PATIENT WITH CONGENITAL HEART DISEASE AND EISENMENGER SYNDROME-Reference-Cited by-同舟云学术

CASE REPORT: THE POSSIBILITY OF SPECIFIC THERAPY OPTIMIZATION BY SWITCHING FROM BOSENTAN TO MACITENTAN IN A PATIENT WITH CONGENITAL HEART DISEASE AND EISENMENGER SYNDROME

Published:2018-03-30 Issue:1 Volume: Page:72-81
ISSN:2305-0748
Container-title:Eurasian heart journal
language:
Short-container-title:Evrazijskij kardiologičeskij žurnal

Author:

Gratsianakaya S. Ye.¹,Arkhipova O. A.¹,Davydov A. I.²,Martynyuk T. V.¹,Ananicheva N. A.³,Belkorey O. S.⁴,Chazova I. Ye.¹

Affiliation:

1. National Medical Research Centre of cardiology of Ministry of Health

2. I.M.Sechenov First Moscow State Medical University

3. S.S. Yudin City Clinical Hospital, Moscow Department of Health

4. City Polyclinic No 218

Abstract

A patient with pulmonary arterial hypertension (PAH) associated with congenital heart disease (ventricular septal defect) and Eisenmenger syndrome was started on an endothelin receptor antagonist bosentan. With treatment, the patient's condition had been stable, however, by the second year, worsening shortness of breath, reduced exercise tolerance and an increase of the right heart were noted. Bosentan was switched to macitentan. After a year of this pathogenetic therapy, an improvement in functional status was registered. Moreover, while on macitentan, the patient has successfully undergone a gynecological surgical procedure under general anesthesia.

Publisher

Intermedservice Ltd

Subject

General Medicine

Reference9 articles.

1. Lowe B.S., Therrien J., Ionescu-Ittu R., et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J. Am. Coll. Cardiol.2011; 58: 538–546. doi: 10.1016/j.jacc.2011.03.033.

2. Сhazova I.Ye., Martynyuk T.V., Nakonechnikov S.N. According to the results of the European congress of cardiology 2015: new version of guidelines for diagnosis and treatment of pulmonary hypertension. Eurasian heart journal, 2015; 4: 3-10 [in Russian].

3. Сhazova I.Ye., Martynyuk T.V. Pulmonary hypertension. M: Practice, 2015 [in Russian].

4. Beghetti M., Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Mar 3; 53(9):733-40. doi: 10.1016/j.jacc.2008.11.025.

5. Galiè N., Beghetti M., Gatzoulis M.A. et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, doubleblind, randomized, placebo-controlled study. Circulation. 2006; 114 (1): 48-54.